NCT00105417 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Benjamin D, Sharma V, Knobloch TJ, Armitage RJ, Dayton MA, Goodwin RG
B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol. 1994 May 15;152(10):4749-57.
Komschlies KL, Grzegorzewski KJ, Wiltrout RH
Diverse immunological and hematological effects of interleukin 7: implications for clinical application. J Leukoc Biol. 1995 Dec;58(6):623-33. Review.
Pandey A, Ozaki K, Baumann H, Levin SD, Puel A, Farr AG, Ziegler SF, Leonard WJ, Lodish HF
Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol. 2000 Jul;1(1):59-64.

A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment (A5214)

Details for clinical trial NCT00105417

Clinical trial NCT00105417 - References